Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease

被引:102
|
作者
Noguchi, M [1 ]
Hiwatashi, N [1 ]
Liu, Z [1 ]
Toyota, T [1 ]
机构
[1] Tohoku Univ, Sch Med, Dept Internal Med 3, Aoba Ku, Sendai, Miyagi 98077, Japan
关键词
Crohn's disease; inflammation; mucosal immunology; soluble TNF receptor; tumour necrosis factor; ulcerative colitis;
D O I
10.1136/gut.43.2.203
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background-Tumour necrosis factor (TNF) alpha and TNF-beta are soluble ligands binding to TNF receptors with similar activities; soluble TNF receptors neutralise TNF activity by acting as inhibitors. Little is known about the cytokine/soluble receptor role in inflammatory bowel disease (IBD). Aims-To test the hypothesis that an imbalance in secretion between TNF and TNF inhibitors plays a role in gut inflammation in patients with IBD. Methods-The secretion of TNF-alpha, TNF-beta, and soluble TNF receptors was compared in the culture supernatants of colonic biopsy specimens and isolated lamina propria mononuclear cells from patients with active colonic IBD. Results-Spontaneous secretion of TNF-alpha in involved IBD mucosa was higher than in normal control and self limited colitis mucosa. Secretion of TNF-beta was higher in patients with Crohn's disease than in those with ulcerative colitis. Soluble TNF receptor in IBD mucosa inhibited TNF activity. Type 2 soluble receptor release from IBD mucosa was increased in active inflammation; release from lamina propria cells was not increased. Mucosal TNF-alpha production correlated with severity of disease. Conclusions-Results showed enhanced secretion of TNF-alpha but failure to release enhanced amounts of soluble TNF receptor in lamina propria mononuclear cells of patients with IBD. An imbalance in secretion between TNF and TNF inhibitor may be implicated in the pathogenesis of IBD.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [21] Methotrexate for psoriasiform lesions associated with anti-tumour necrosis factor therapy in inflammatory bowel disease
    Buisson, A.
    Cuny, J. -F.
    Barbaud, A.
    Schmutz, J. -L.
    Bigard, M. -A.
    Gueant, J. -L.
    Peyrin-Biroulet, L.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (10) : 1175 - 1180
  • [22] Review article: paradoxical psoriasis as a consequence of tumour necrosis factor antagonists in patients with inflammatory bowel disease
    Townsend, Cassandra Marie
    Lovegrove, Fiona
    Khanna, Reena
    Wilson, Aze Suzanne
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 55 (11) : 1379 - 1388
  • [23] ANTI-TUMOUR NECROSIS FACTOR-ALFA DRUG MONITORING IN PAEDIATRIC INFLAMMATORY BOWEL DISEASE
    Muhammed, R.
    Wong, T.
    Haller, W.
    Bremner, R.
    Protheroe, S.
    GUT, 2015, 64 : A432 - A433
  • [24] Paradoxical psoriasiform reactions of anti-tumour necrosis factor therapy in inflammatory bowel disease patients
    Peer, Faseeha C.
    Miller, Andrew
    Pavli, Paul
    Subramaniam, Kavitha
    INTERNAL MEDICINE JOURNAL, 2017, 47 (12) : 1445 - 1448
  • [25] Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease
    Brynskov, J
    Foegh, P
    Pedersen, G
    Ellervik, C
    Kirkegaard, T
    Bingham, A
    Saermark, T
    GUT, 2002, 51 (01) : 37 - 43
  • [26] The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease
    Shale, Matthew J.
    BRITISH MEDICAL BULLETIN, 2009, 92 (01) : 61 - 77
  • [27] Oral manifestations in inflammatory bowel disease patients under anti-tumour necrosis factor treatment
    Barreiro-de Acosta, M.
    Rio, P.
    Ferreiro, R.
    Bouza, M. J.
    Pombo, M. D. C.
    Lorenzo, A.
    Gallas, M.
    Dominguez-Munoz, J. E.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S202 - S203
  • [28] Tumour necrosis factor alpha in non-inflammatory bowel disease enterocutaneous fistulas prospective study
    Rahbour, G.
    Al-Hassi, H. O.
    Hart, A. L.
    Ullah, M. R.
    Gabe, S. M.
    Knight, S. C.
    Warusavitarne, J.
    Vaizey, C. J.
    IMMUNOLOGY, 2012, 137 : 536 - 537
  • [29] Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease
    Deepak, P.
    Stobaugh, D. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (09) : 1035 - 1043
  • [30] Tumour necrosis factor alpha in non-inflammatory bowel disease enterocutaneous fistulas prospective study
    Rahbour, G.
    Al-Hassi, H. O.
    Hart, A. L.
    Ullah, M. R.
    Gabe, S. M.
    Knight, S. C.
    Warusavitarne, J.
    Vaizey, C. J.
    BRITISH JOURNAL OF SURGERY, 2013, 100 : 37 - 37